Evaluating AT-02 for systemic amyloidosis and healthy volunteers

A Three-part, Phase 1, Single-ascending, and Multiple-ascending Dose Escalation Study in Healthy Volunteers and Subjects With Systemic Amyloidosis to Assess the Safety, Tolerability, and Pharmacokinetics of AT-02

This study is testing a new medication called AT-02 to see how safe it is and how the body processes it in people with systemic amyloidosis and healthy volunteers.

Quick facts

• Phase: Phase 1
• Study type: Interventional
• Enrollment: 100 (estimated)
• Ages: 18 Years and up
• Sex: All
• Sponsor: Attralus, Inc. (Industry-sponsored)
• Drugs / interventions: daratumumab
• Locations: 11 sites (Overland Park, Kansas and 10 other locations)
• Trial ID: NCT05521022 on ClinicalTrials.gov

What this trial studies

This Phase 1 clinical trial is designed to assess the safety, tolerability, and pharmacokinetics (PK) of AT-02, a monoclonal antibody, in both healthy volunteers and patients with systemic amyloidosis. The study consists of three parts: a single-ascending dose escalation in healthy volunteers, a single-ascending dose escalation in patients with systemic amyloidosis to determine the maximum tolerated dose, and a multiple-ascending dose study in patients with systemic amyloidosis. The trial aims to gather critical data on how AT-02 is processed in the body and its safety profile.

Who should consider this trial

Good fit: Ideal candidates include adults over 18 years with a diagnosis of systemic amyloidosis.

Not a fit: Patients with other forms of amyloidosis or those who do not meet the eligibility criteria will not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could significantly improve outcomes for patients with systemic amyloidosis, a condition with currently limited treatment options.

How similar studies have performed: While there have been advancements in treatments for systemic amyloidosis, this specific approach with AT-02 is novel and has not been extensively tested in prior studies.

Eligibility criteria

Inclusion Criteria:

Eligibility Criteria for Healthy Volunteers:

Healthy volunteers are eligible to be included in the study only if all the following criteria apply:

1. Understands the study procedures and can give signed informed consent
2. Male or female between \>18 and \<56 years of age.
3. Willing and able to comply with this protocol and informed consent and be available for the entire duration of the study.
4. Willing to abstain from alcohol and strenuous physical activity (i.e., strenuous or unaccustomed weightlifting, running, bicycling, etc.) from 48 hours prior to study treatment administration until discharge from the clinical unit and prior to each outpatient visit.
5. In good general health, determined by no clinically significant findings in the opinion of the Investigator from medical history, physical examination, 12-lead electrocardiogram (ECG), clinical laboratory findings, and vital signs at Screening and Phase 1 unit Check-in.
6. Has body mass index (BMI) of 18 to 32 kg/m2, inclusive.
7. Women of childbearing potential (WOCBP)

   1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study drug.
   2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.
   3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.
8. Postmenopausal females:

   a) Postmenopausal females under the age of 55 years must have a documented serum follicle stimulating hormone (FSH) level \>40 mIU/mL to confirm menopause
9. Women of non-childbearing potential (WONCBP) and female participants with vasectomized male partners:

   a) WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.
10. Male participants:

    1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.
    2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.
    3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.
    4. Male participants with potentially postmenopausal partners who are under the age of 55 years must use condoms unless their partner's postmenopausal status has been confirmed by FSH level.
    5. Male participants in same-sex relationships or in relationships with WONCBP must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.

Eligibility Criteria for Part 2 Subjects with Systemic Amyloidosis

Subjects with systemic amyloidosis are eligible to be included in the study only if all the following criteria apply:

1. Understands the study procedures and can give signed informed consent
2. Male or female ≥18 and ≤80 years of age.
3. Mini Mental Status Exam (MMSE) score \>27 (subjects \>55 years of age only).
4. Has a confirmed diagnosis of AL, ATTR, or other form of systemic amyloidosis, based on any one of the following:

   1. A histologic confirmation with a biopsy containing deposits of apple-green birefringent, Congophilic material or other amyloid staining (i.e., thioflavin T or sulfated alcian blue) with confirmatory immunohistochemistry, mass spectrometry or identification of an amyloidogenic genetic variant;
   2. Genetic screening with presence of amyloid-related pathology; or
   3. Amyloid-specific imaging study (e.g., bone scintigraphy and echocardiogram/CMR consistent with ATTR cardiac amyloid).
5. Subjects with AL systemic amyloidosis must have achieved a hematologic very good partial response (VGPR) or complete response (CR) based on their most recent assessment (e.g., difference in free light chains \<40 mg/L) and within 12 months of Screening and may be receiving maintenance daratumumab.
6. Subjects with ATTR systemic amyloidosis may be receiving a TTR silencer (e.g., inotersen, vutrisiran, or patisiran) or a stabilizer (e.g., tafamadis or diflunisal), but not both.
7. Women of childbearing potential (WOCBP):

   1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.
   2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.
   3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.
8. Women of non-childbearing potential (WONCBP), and female participants with vasectomized male partners:

   1. WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.
   2. Postmenopausal females must have a documented serum FSH level \>40 mIU/mL at Screening to confirm menopause.
9. Male participants:

   1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.
   2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.
   3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.
   4. Male participants in same-sex relationships or in relationships with WONCBP, must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.

Eligibility Criteria for Part 3 Subjects with Systemic Amyloidosis

Subjects with systemic amyloidosis are eligible to be included in the study only if all the following criteria apply:

1. Understands the study procedures and can give signed informed consent.
2. Male or female ≥18 and ≤85 years of age.
3. Has a confirmed diagnosis of ATTR cardiomyopathy (ATTR-CM), AL, or other form of systemic amyloidosis
4. Imaging evidence of organ amyloid deposits.
5. For ATTR cardiomyopathy subjects, genetic testing confirming wild type ATTR or identification of an amyloidogenic genetic variant is required. If genetic testing has not been performed prior to screening, then the test may be ordered during screening
6. Subjects with ATTR cardiomyopathy may be receiving a TTR silencer (e.g., inotersen, vutrisiran, or patisiran) or a stabilizer (e.g., tafamadis or diflunisal), but not both.
7. Subjects with AL systemic amyloidosis may be receiving maintenance daratumumab and must have

   1. Achieved a hematologic very good partial response (VGPR) or complete response (CR) based on their most recent assessment (e.g., difference in free light chains \<40 mg/L) within 12 months of Screening or
   2. Achieved a partial hematologic response, is in stable condition (defined as \>6 months without clonal or amyloidotic organ progression), is not receiving plasma cell directed (PCD) therapy and is not expected to require PCD therapy for the duration of the study.
8. Women of childbearing potential (WOCBP):

   1. WOCBP must have a negative serum or urine pregnancy test within 24 hours prior to the start of study treatment.
   2. Must not be breastfeeding, lactating, or planning a pregnancy during the study period.
   3. WOCBP who are not exclusively in same-sex relationships must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 105 days after the last dose of study intervention.
9. Women of non-childbearing potential (WONCBP), and female participants with vasectomized male partners:

   1. WONCBP must agree to remain abstinent (complete avoidance of intercourse) or the male partners of WONCBP participants must wear a condom to protect against the transfer of study intervention through bodily fluids during the treatment period and for at least 105 days after the last dose of study intervention.
   2. Postmenopausal females must have a documented serum FSH level \>40 mIU/mL at Screening to confirm menopause.
10. Male participants:

    1. Male participants must inform their female sexual partners who are WOCBP of the contraceptive requirements of the protocol and are expected to adhere to using contraception with their partner.
    2. Male participants with female sexual partners who are WOCBP must agree to remain abstinent (complete avoidance of heterosexual intercourse) or use adequate contraceptive methods, defined as use of a condom by the male partner combined with use of a highly effective method of contraception by the female partner, during the treatment period and for at least 165 days after the last dose of study intervention.
    3. Male participants must not donate sperm for at least 165 days after the last dose of study intervention.
    4. Male participants in same-sex relationships or in relationships with WONCBP must agree to remain abstinent (complete avoidance of intercourse) or use a condom to prevent exposure of the partner to study intervention through ejaculate/seminal fluid during the treatment period and for at least 165 days after the last dose of study intervention.

Where this trial is running

Overland Park, Kansas and 10 other locations

• Midwest Heart and Vascular — Overland Park, Kansas, United States (Recruiting)
• Johns Hopkins — Baltimore, Maryland, United States (Recruiting)
• St. Luke's Hospital of Kansas City — Kansas City, Missouri, United States (Recruiting)
• Cleveland Clinic — Cleveland, Ohio, United States (Recruiting)
• OHSU (Oregon Health & Science University) — Portland, Oregon, United States (Recruiting)
• Penn Presbyterian Medical Center — Philadelphia, Pennsylvania, United States (Recruiting)
• Q-Pharm Pty Ltd — Herston, Queensland, Australia (Recruiting)
• Princess Alexandra Hospital — Woolloongabba, Queensland, Australia (Recruiting)
• Flinders Medical Centre — Bedford Park, South Australia, Australia (Recruiting)
• Box Hill Hospital — Box Hill, Victoria, Australia (Recruiting)
• Royal Perth Hospital — Perth, Western Australia, Australia (Recruiting)

Study contacts

• Study coordinator: Scott Stephens, RN

Conditions Amyloidosis; Systemic